CRIS

Curis, Inc.
CAPPED RATING

Curis Inc is a biotechnology company engaged in developing and commercializing drug candidates for the treatment of human cancers.

Curis, Inc. (CRIS) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
B+
Factor Score 3.5 / 5.0
Growth
B-
Factor Score 3.1 / 5.0
Profitability
D
Factor Score 1.2 / 5.0
Momentum
F
Factor Score 0.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.5
EV / EBITDA 0.1
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -61.1%
Price Return 12M -97.5%
Catalyst Signal 0.00
Market Cap $4.4M
TTM Revenue $4.3M
Price / Sales 1.0
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B+ (3.5) B- (3.1) D (1.2) F (0.6) C+ (2.6) C (2.2)
2026-11-04 B+ (3.5) B- (3.1) D (1.2) F (0.3) C+ (2.7) C (2.2)
2026-10-28 B (3.5) B- (3.0) D (1.2) F (0.3) C+ (2.7) C- (2.1)
2026-10-21 B+ (3.5) B- (3.0) D (1.2) F (0.3) C+ (2.6) C- (2.1)
2026-10-14 B (3.5) B- (3.0) D (1.2) F (0.3) C+ (2.6) C- (2.1)
Page 1 of 7